This company listing is no longer active
Cerevel Therapeutics Holdings Management
Management criteria checks 2/4
Cerevel Therapeutics Holdings' CEO is Ron Renaud, appointed in Jun 2023, has a tenure of less than a year. directly owns 0.13% of the company’s shares, worth €9.25M. The average tenure of the management team and the board of directors is 3.3 years and 5 years respectively.
Key information
Ron Renaud
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
CEO
Ron Renaud (54 yo)
less than a year
Tenure
Mr. Ronald C. Renaud, also known as Ron, Jr., M.B.A., serves as President, CEO & Director at Cerevel Therapeutics Holdings, Inc. since June 12, 2023. He served as Managing Director at Bain Capital Life Sci...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.3yrs | US$11.23m | 0.0086% € 592.2k | |
| VP of Finance & Chief Accounting Officer | 4.5yrs | US$1.58m | 0.0098% € 671.3k | |
| Chief Scientific Officer | 4.9yrs | US$4.78m | 0.0035% € 241.4k | |
| Chief Medical Officer | 5.2yrs | US$4.81m | 0.0081% € 555.8k | |
| President | less than a year | no data | 0.13% € 9.3m | |
| Chief Financial Officer | less than a year | no data | 0.0093% € 640.4k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 2.8yrs | US$3.19m | 0.0040% € 274.4k | |
| Chief Human Resources Officer | 4.9yrs | no data | 0.014% € 934.1k | |
| Chief Corporate Affairs Officer | 3.7yrs | US$3.92m | 0.0059% € 403.8k | |
| Chief Business Development & Strategic Operations Officer | less than a year | no data | 0.025% € 1.7m |
3.3yrs
Average Tenure
53yo
Average Age
Experienced Management: 673's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.3yrs | US$11.23m | 0.0086% € 592.2k | |
| President | less than a year | no data | 0.13% € 9.3m | |
| Independent Director | 4.8yrs | US$510.98k | 0.025% € 1.7m | |
| Independent Director | 5.5yrs | US$499.32k | 0.016% € 1.1m | |
| Independent Director | 3.2yrs | US$485.48k | 0% € 0 | |
| Lead Independent Director | 5.3yrs | US$562.57k | 0.024% € 1.6m | |
| Independent Director | 5.5yrs | US$497.15k | 0% € 0 | |
| Independent Director | 5.5yrs | US$492.98k | 0% € 0 | |
| Independent Director | 5.5yrs | US$497.15k | 0% € 0 | |
| Independent Director | 3.3yrs | US$485.48k | 0% € 0 | |
| Independent Director | 1.8yrs | no data | no data | |
| Independent Director | 3.2yrs | no data | no data |
5.0yrs
Average Tenure
63yo
Average Age
Experienced Board: 673's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/02 23:51 |
| End of Day Share Price | 2023/12/04 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cerevel Therapeutics Holdings, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Esther Lannie Hong | Berenberg |
| Tazeen Ahmad | BofA Global Research |